Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aspirin every 12 hours after CABG and/or bioprosthetic aortic valve surgery
2011-001488-40Phase 2Active
- Sponsor
- Centro Cardiologico Monzino
- Start
- Mar 2012
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of aspirin in coronary arteriosclerosis and aortic valve disease (AVD) (3 arms), sponsored by Centro Cardiologico Monzino. Primary endpoints: Variation of serum TXB2 at 12 and 24 hours after aspirin administration and Variation of serum 12-HETE at 12 and 24 hours after aspirin administration. Started Mar 2012; status: active.
02
Drugs
aspirin
03
Conditions
coronary arteriosclerosisaortic valve disease (AVD)
Beyond the preview
Go deeper on 2011-001488-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-001488-40.